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The proteins Foxa1 and Foxa2 belong to the forkhead family of transcription factors
and are involved in the development of several tissues, including liver, pancreas, lung,
prostate, and the neural system. Both Foxa1 and Foxa2 are also crucial for the specification
and differentiation of dopamine (DA) neurons during embryonic development, while
about 30% of mice with an embryonic deletion of a single allele of the Foxa2 gene
exhibit an age-related asymmetric loss of DA neurons and develop locomotor symptoms
resembling Parkinson’s disease (PD). Notably, both Foxa1 and Foxa2 factors continue to
be expressed in the adult dopamine system. To directly assess their functions selectively
in adult DA neurons, we induced genetic deletions of Foxa1/2 transcription factors in
mice using a tamoxifen inducible tissue-specific CreERT2 recombinase expressed under
control of the dopamine transporter (DAT) promoter (DATCreERT2). The conditional DA
neurons-specific ablation of both genes, but not of Foxa2 alone, in early adulthood, caused
a decline of striatal dopamine and its metabolites, along with locomotor deficits. At early
pre-symptomatic stages, we observed a decline in aldehyde dehydrogenase family 1,
subfamily A1 (Aldh1a1) protein expression in DA neurons. Further analyses revealed
a decline of aromatic amino acid decarboxylase (AADC) and a complete loss of DAT
expression in these neurons. These molecular changes ultimately led to a reduction of DA
neuron numbers in the substantia nigra pars compacta (SNpc) of aged cFoxa1/2−/− mice,
resembling the progressive course of PD in humans. Altogether, in this study, we
address the molecular, cellular, and functional role of both Foxa1 and Foxa2 factors in
the maintenance of the adult dopamine system which may help to find better approaches
for PD treatment.
Keywords: Foxa1, Foxa2, dopamine, dopaminergic neurons, transgenic mice, neurodegeneration, substantia nigra,
Parkinson’s disease
INTRODUCTION
Parkinson’s disease (PD) is one of the most prevalent age-related
movement disorders occurring in about 1% of the population
above the age of 60 (Abou-Sleiman et al., 2006; Ferri et al., 2007).
PD affects multiple neuronal systems (Braak et al., 2003), how-
ever, the major motor symptoms are caused by the degeneration
of dopamine (DA) neurons in the substantia nigra pars compacta
(SNpc) (Moore et al., 2005). Current treatment strategies are pro-
viding only symptomatic relief to the patients and are not able
to prevent the progression of neurodegeneration. Therefore, the
identification and characterization of the mechanisms involved
Abbreviations: AADC, aromatic amino acid decarboxylase; Aldh1a1, aldehyde
dehydrogenase family 1, subfamily A1; ChIP, chromatin immunoprecipitation;
DA, dopamine; DAT, dopamine transporter; DOPAC, 3,4-dihydroxyphenylacetic
acid; DOPAL, 3,4-dihydroxyphenylacetaldehyde; En1, engrailed 1; HPLC-ED,
high-performance liquid chromatography with electrochemical detection; HVA,
homovanillic acid; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD,
Parkinson’s disease; post-TAM, after tamoxifen treatment; rpm, rounds perminute;
s.e.m., standard error of means; SNpc, substantia nigra pars compacta; TAM,
tamoxifen; TH, tyrosine hydroxylase; VTA, ventral tegmental area.
in the maintenance of adult DA neurons is critically important
for the advance of novel therapies for PD (Meissner et al., 2011).
The development of midbrain DA neurons is a highly orches-
trated process involving coordinated action of multiple signaling
molecules and transcription factors, such as Shh, Wnt, Otx2,
Pitx3, Nurr1 (Nr4a2), Foxa1, and Foxa2 (Perlmann and Wallen-
Mackenzie, 2004; Ferri et al., 2007; Smidt and Burbach, 2007;
Omodei et al., 2008; Jacobs et al., 2009; Joksimovic et al.,
2009; Mesman et al., 2014). Several of these factors continue
to be expressed in post-mitotic and also in adult DA neu-
rons contributing to the functional maintenance of this neu-
ronal population. For example, Otx2 expressed in the ventral
tegmental area (VTA) DA neurons controls the identity of this
neuronal subtype and confers its resistance to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Di Salvio et al., 2010; Di
Giovannantonio et al., 2013). A selective ablation of orphan
nuclear receptor Nurr1 in adult DA neurons using a tamox-
ifen (TAM)-inducible Cre/LoxP recombination system leads to
the fiber pathology of this neuronal population and loss of
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striatal dopamine, recapitulating early stages of PD development
(Kadkhodaei et al., 2009). It has recently been shown that Nurr1
regulates the expression of nuclear-encoded mitochondrial genes
and is involved in sustaining high respiratory function in adult
DA neurons (Kadkhodaei et al., 2013). Transcription factors
Foxa1 and Foxa2 play crucial roles not only during the early devel-
opment and specification (Ferri et al., 2007; Kittappa et al., 2007;
Moore et al., 2005), but also in the process of maturation of
DA neurons, as has been demonstrated by deleting these factors
in post-mitotic DA neurons during late embryonic development
(Stott et al., 2013). Interestingly, an asymmetrical degeneration
of SNpc DA neurons has been observed in about 30% of aged
mice bearing a global heterozygous deletion of Foxa2 gene allele
(Kittappa et al., 2007).
Proteins belonging to Foxa family (Foxa1, Foxa2, and Foxa3)
share very high sequence homology within the DNA binding
domain, whereas outside of this region they are less similar,
and Foxa3 being shorter and more divergent from Foxa1/2 (Lai
et al., 1991; Friedman and Kaestner, 2006; Kaestner, 2010).
The loss-of-function studies demonstrate that Foxa1 and Foxa2
have partially overlapping functions during embryonic develop-
ment of DA neurons; both Foxa1 and Foxa2 factors are required
for the expression of Lmx1a, Lmx1b (Lin et al., 2009), Nurr1
and engrailed 1 (En1) (Ferri et al., 2007) in immature DA
neurons and for the expression of AADC and TH in early
post-mitotic DA neurons (Ferri et al., 2007; Stott et al., 2013).
Consequently, a combined deletion of Foxa1 and Foxa2 in embry-
onic DA neurons results in reduced binding of Nurr1 to Th
and Aadc gene promoters leading to a significant loss of TH
and AADC expression in the SNpc of embryos and adult mice
(Stott et al., 2013).
The expression of both Foxa1 and Foxa2 continues into adult-
hood (Kittappa et al., 2007; Stott et al., 2013), suggesting that,
in addition to their essential role in the development, specifi-
cation and maturation, both proteins are also involved in the
physiological functions of adult DA neurons.
The deregulation of Foxa1/2 may also contribute to demise
of DA neurons during PD progression in humans. Indeed, by
searching the online databases, such as the National Center
for Adult Stem Cell Research Parkinson’s review database
(Sutherland et al., 2009) and ParkDB (Taccioli et al., 2011) that
contain manually curated, re-analyzed and annotated microar-
ray datasets from PD patients and PD models, we found
several datasets showing the down-regulation of Foxa1 and
Foxa2 expression in the SNpc of PD patients (Hauser et al.,
2005; Zhang et al., 2005; Moran et al., 2006; Lesnick et al.,
2007).
However, no previous studies have directly addressed the role
of Foxa1/2 factors in adult DA neurons. Here we used a tissue-
specific TAM-inducible Cre recombination to ablate both the
Foxa1 and Foxa2 genes selectively in adult DA neurons. This dele-
tion resulted in DA neurons losing their dopaminergic pheno-
type, which was reflected by the decline in expression of Aldh1a1,
AADC, DAT and TH, as well as reduced striatal dopamine
leading to the development of locomotor abnormalities, and,
ultimately, loss of the neurons in aged cFoxa1/2−/− double
knockout mice.
MATERIALS AND METHODS
ANIMAL EXPERIMENTS
Mice were maintained in the C57Bl/6N genetic background
on a 12 h light-dark cycle with free access to water and
food. The Foxa2fl/flDATCreERT2, Foxa1fl/wtFoxa2fl/flDATC
reERT2, Foxa1fl/flFoxa2fl/wtDATCreERT2, and Foxa1fl/flFoxa2fl/fl
DATCreERT2 mouse lines (referred hereafter as cFoxa2−/−,
cFoxa1+/−/2−/−, cFoxa1−/−/2+/−, and cFoxa1/2−/−, respec-
tively) were generated by mating Foxa1fl/fl (Gao et al., 2008) and
Foxa2fl/fl mice (Sund et al., 2000) with DATCreERT2 (Engblom
et al., 2008) mice. Inducible Cre recombinase was activated in
8–10 week-old mice by intraperitonial injections of 1mg tamox-
ifen (TAM, Sigma-Aldrich) diluted in sunflower oil twice daily
for five consecutive days (Domanskyi et al., 2011; Rieker et al.,
2011; Vinnikov et al., 2014). Littermates harboring only floxed
alleles were used as controls. All experimental procedures were
performed with the approval by the institutional Committee on
Ethics of Animal Experimentation and carried out in accordance
with the local and European legislation on the protection of
animals used for scientific purposes.
HISTOLOGICAL ANALYSES
Mice at the indicated time points after TAM injections (post-
TAM) were perfused with 4% paraformaldehyde (PFA);
the brains were dissected and fixed overnight in 4% PFA
and processed for either paraffin or vibratome sections.
Upon dissection, no differences in morphology, weight, or
size of the brains were observed in cFoxa1/2 animals com-
pared to control littermates. Immunohistochemical and
immunofluorescent stainings were performed as previously
described (Domanskyi et al., 2011; Rieker et al., 2011) using
the following antibodies: anti-tyrosine hydroxylase (TH)
(1:1000, Millipore #AB1542), anti-aromatic amino acid decar-
boxylase (AADC) (1:1000, Millipore #AB1569), anti-DAT
(1:500, Millipore #MAB369), anti-aldehyde dehydrogenase
1 family, member A1 (Aldh1a1) (1:100, Abcam #ab52492).
Fluorescent signals in the brain samples were visualized
directly with confocal system TSC SP5 (Leica) or LSM780
(Zeiss).
Quantification of the Aldh1a1- and TH-positive cells on
immunostained brain sections was performed either by blinded
experimenters or by using MCID Image Analysis software
(InterFocus Imaging) as previously described (Isermann et al.,
2007; Domanskyi et al., 2011). The SNpc and the VTA were
identified according to the anatomical landmarks (Zaborszky and
Vadasz, 2001) and the neurons were counted for eachmouse from
at least five sections covering the ventral midbrain (Domanskyi
et al., 2011). For immunofluorescently stained samples, number
of TH-positive neurons in the SNpc and VTA in single confocal
plane images was determined by blinded investigators, followed
by a quantification of the percentage of Aldh1a1-positive neu-
rons within the TH-positive population on the same sections.
Quantification of immunohistochemically stained TH-positive
neurons in aged cFoxa1/2−/−mice was performed in the same
way, except that the region of interest was limited by the SNpc
and that counting was performed automatically by MCID Image
Analysis software.
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QUANTITATIVE RT-PCR
Total RNA isolated from ventral midbrain samples served as a
template for DNA synthesis using Super-Script III first-strand
synthesis kit (Invitrogen). For genomic DNA contamination con-
trol, samples with no added reverse transcriptase enzyme were
included. Quantitative PCR was performed with a CFX96 Real-
Time System (Bio-Rad) using TagMan Gene Expression Assays
(Life Technologies) according to the manufacturer’s instructions.
The mRNA levels of Hprt1 were measured to control for the
equal amount of input cDNA. The following probes were
used for detection of En1, Foxa1, Foxa2, Hprt1, Lmx1b, Nr4a2,
Pitx3, Th, and Ucp2: Mm00438709_m1, Mm00484713_m1,
Mm00839704_mH, Mm01545399_m1, Mm00440209_m1,
Mm00443056_m1, Mm01194166_g1, Mm00447557_m1, and
Mm00495907_g1, respectively.
BEHAVIORAL ASSAYS
The accelerating and constant speed rotarod assays were per-
formed as previously described (Domanskyi et al., 2011; Rieker
et al., 2011). Briefly, for the constant speed rotarod assay mice
were initially trained to attain stable baseline levels of perfor-
mance staying on the rod rotating at 15 rpm for 60 s. After that,
the mice received several trials at 25 and 35 rpm rotation speed
with 60 s maximum trial length and 5min intervals between indi-
vidual trials. Two maximal values per speed per day were used
to calculate the average which was used for subsequent statistical
analyses. This setting successfully corrects for effects unrelated to
motor/balance performance such as re-learning, fatigue, tenden-
cies to learned helplessness or over-performance/hyperactivity.
For the open field test, mice were placed individually into the
open arena and monitored for 5min by a video camera. The
resulting data were analyzed using the image processing systems
EthoVision 3.0 (Noldus Information Technology) (Chourbaji
et al., 2008) and Any-maze 4.82 (Stoelting Co.). For each sam-
ple, the systems recorded position, object area and the status of
defined events.
MEASUREMENTS OF STRIATAL DOPAMINE AND ITS METABOLITES
After decapitation, the striata were rapidly dissected on ice,
weighed, and frozen on dry ice. Measurements of stri-
atal dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) were performed by reverse-phase HPLC
with electrochemical detection method (HPLC-ED) as previously
described (Otto and Unsicker, 1990; Enkel et al., 2014).
STATISTICAL ANALYSES
Statistical significance was calculated by Student’s two-tailed
unpaired t-test or Two-Way ANOVA followed by Bonferroni post-
hoc test using GraphPad Prism software (GraphPad Scientific,
USA). p values less than 0.05 were considered significant
(∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001) with respect to control
groups. Data in text and figures are represented as means± s.e.m.
RESULTS
Foxa2 DELETION IN ADULT DOPAMINE NEURONS DOES NOT LEAD TO
NEURODEGENERATION
To directly investigate the role of Foxa2 in maintenance of adult
DA neurons, we crossed Foxa2fl/fl mice (Sund et al., 2000) with
the DATCreERT2 line. These transgenic mice provide a tight
spatial and temporal control of recombination upon treatment
with estrogen receptor antagonist TAM (Engblom et al., 2008).
In cFoxa2−/− mice harboring deletions of both Foxa2 alleles in
adult DA neurons, no sign of neurodegeneration phenotype was
observed at any time point tested (Figures 1A–C). Both striatal
dopamine content (Figure 1A) andmotor functions, measured in
the accelerated rotarod assay (Figure 1B) or in the more sensitive
(Monville et al., 2006; Brooks and Dunnett, 2009) constant speed
rotarod assay (Figure 1C), were at normal levels in cFoxa2−/−
mice up to 58 weeks after recombination onset by TAM treatment
(post-TAM) (Figures 1A,C).
The previous works delineating the role of Foxa factors in the
liver, pancreas and developing DA neurons (Ferri et al., 2007;
Kaestner, 2010; Stott et al., 2013) have detected striking similar-
ities in binding motifs, regulated genes and global functions of
Foxa1 and Foxa2 factors, indicating that Foxa1 could compensate
for the function of Foxa2 in adult DA neurons of cFoxa2−/− mice.
Indeed, despite significant down-regulation of Foxa2 mRNA lev-
els in the ventral midbrain of cFoxa2−/− mice, the levels of Foxa1
in these animals were up-regulated (Figure 1D). These results
imply the existence of a functional overlap between Foxa1 and
Foxa2 in adult DA neurons.
Foxa1/2 DELETION IN ADULT DOPAMINE NEURONS CAUSES
LOCOMOTOR DEFICITS
In order to conditionally ablate both Foxa1 and Foxa2 fac-
tors in adult DA neurons, we created cFoxa1/2−/− mice by
crossing Foxa1fl/fl (Gao et al., 2008) and Foxa2fl/fl (Sund
et al., 2000) with DATCreERT2 (Engblom et al., 2008) ani-
mals. The quantitative PCR (qPCR) analysis showed that both
Foxa1 and Foxa2 mRNA expression in the ventral midbrain
decreased in cFoxa1/2−/− mice (Table 1), confirming the suc-
cessful deletion of Foxa1 and Foxa2 in these animals. Starting
from the 18th week post-TAM, cFoxa1/2−/− mice developed
locomotor impairments, as determined by the constant speed
rotarod assay (Figures 2A,B). Importantly, when tested at 21
weeks post-TAM, the mice exhibited a decreased activity in
the open field test paralleled by an increased circling behavior
(Figures 2C–E). The asymmetric circling behavior (Figure 2D)
in cFoxa1/2−/− mice may partly be due to an increased dif-
ference in dopamine levels in left and right brain hemispheres
(Supplementary Figure 1). Moreover, at 24 weeks post-TAM
we observed a significant reduction of the striatal content of
dopamine and its metabolites, DOPAC and HVA (Table 2) in
cFoxa1/2−/− mice.
LOSS OF Aldh1a1 EXPRESSION IN THE VENTRAL MIDBRAIN PRECEDES
THE ONSET OF LOCOMOTOR IMPAIRMENTS IN cFoxa1/2−/− MICE
At the same time point, 24 weeks post-TAM, the numbers
of TH-positive neurons both in the SNpc and in the VTA of
cFoxa1/2−/− mice were normal (Figures 3A,B). However, already
at 11 weeks post-TAM, we observed a dramatic decrease of the
numbers of Aldh1a1-positive DA neurons (Figure 3C) that was
even more evident at 24 weeks and was stronger in the SNpc
than in the VTA (Figures 3D–G). Aldh1a1 is neuroprotective in
DA neurons (Anderson et al., 2011; Wey et al., 2012; Liu et al.,
2014) and, therefore, decline in its expression may render adult
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FIGURE 1 | Absence of changes in locomotor activity and striatal
dopamine content upon conditional ablation of Foxa2 gene in adult
dopamine neurons. (A) Striatal dopamine content in cFoxa2−/− mice at
indicated time points after TAM treatment (post-TAM). n = 4, 3, 3, 7, 14, 10,
6, 6, 5, 3 for the groups from left to the right on the graph. (B) Latency to fall
in the accelerating rotarod assay in control, cFoxa2+/−, and cFoxa2−/− mice
6 weeks post-TAM (n = 4, 3, 3, respectively). (C) Latency to fall in the
constant speed (35 rpm) rotarod assay in aged control, cFoxa2+/−, and
cFoxa2−/− mice 58 weeks post-TAM (n = 3, 15, 9, respectively). (D)
Reciprocal change of Foxa1 and Foxa2 mRNA levels in the ventral midbrain of
control (n = 10) and cFoxa2−/− (n = 5) mice 24 weeks post-TAM. ∗p < 0.05
in comparison to control, as determined by Student’s unpaired t-test.
Table 1 | Relative levels of Foxa1 and Foxa2 mRNA in the ventral midbrain of mice 24 weeks after conditional ablation of these factors in adult
dopamine neurons.
Line name Genotype n Foxa1 (%) Foxa2 (%)
Control Foxa1fl/flFoxa2fl/fl 10 100± 11.64 100± 10.36
cFoxa2−/− Foxa2fl/flDATCreERT2 5 183.24± 27.05* 66.56± 10.21*
cFoxa1+/−/2−/− Foxa1fl/wtFoxa2fl/flDATCreERT2 10 122.32± 19.94 61.1± 8.24**
cFoxa1/2−/− Foxa1fl/flFoxa2fl/flDATCreERT2 5 54.93± 13.04* 68.25± 7.35*
The data, presented as mean values ± s.e.m., are normalized to the Hprt1 levels and expressed as percentage relative to control; *p < 0.05, **p < 0.01 in
comparison to control, as determined by Student’s unpaired t-test.
DA neurons toward degeneration. Accordingly, even though
the numbers of TH-positive neurons at 24 weeks post-TAM
cFoxa1/2−/− mice did not change, these neurons exhibited a
decrease in the ventral midbrain expression of the key proteins in
the DA metabolism: TH, AADC, and especially DAT, as detected
in immunostaining experiments (Figures 4A–C). Furthermore,
at 24 weeks post-TAM, when we analyzed the expression of
several transcripts important for development and functionality
of DA neurons (Smidt and Burbach, 2007), we observed a
tendency towards decrease of En1 and Th (Supplementary
Figure 2). This data suggests that Foxa1/2 proteins are essential
in maintaining the expression of crucial factors in adult DA
neurons. Indeed, Foxa2 has previously been shown to regulate
En1 expression (Ferri et al., 2007). Moreover, it can directly bind
to Th gene promoter and cooperate with Nurr1 in regulating the
expression of TH and AADC in the ventral midbrain (Lee et al.,
2010; Stott et al., 2013). Interestingly, the mRNA level of Ucp2
encoding a mitochondrial uncoupling protein was up-regulated
in cFoxa1/2−/− mice (Supplementary Figure 2). Overexpression
of Ucp2 has been shown to decrease mitochondrial production
of reactive oxygen species (Andrews et al., 2005) and protect
DA neurons from MPTP (Conti et al., 2005), and Ucp2 mRNA
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FIGURE 2 | Locomotor impairments in cFoxa1/2−/− double mutant
mice. (A,B) Latency to fall in the constant speed rotarod assay at 35 rpm (A)
and 25 rpm (B) in control and cFoxa1/2−/− mice (n = 13 and 5, respectively)
at indicated time points post-TAM (C–E) The quantification of mean velocity
(C) and mean angular velocity (D), and representative running tracks (E) of
control, cFoxa2−/−, cFoxa1+/−/2−/−, and cFoxa1/2−/− mice (n = 11, 6, 10, 5,
respectively) in the open field assay performed 21 weeks post-TAM. Length
of the open field box side, 60 cm. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 in
comparison to control, as determined by Student’s unpaired t-test or
Two-Way ANOVA followed by Bonferroni post-hoc test. Blue and red dots
represent, respectively, the initial and final position of a mouse in the open
field assay.
up-regulation may indicate the existence of a compensatory
mechanism which might be activated to protect mitochondrial
function in cFoxa1/2−/− mice.
Ultimately, we observed a down-regulation of striatal
dopamine (Figure 5A) and the loss of TH-positive neurons in the
ventral midbrain of aged cFoxa1/2−/− mice 78 weeks post-TAM,
visualized by TH and AADC immunostaining and quantifica-
tion of the TH-positive neurons in the SNpc (Figures 5B–D).
Thus, in the early adulthood of cFoxa1/2−/− mice, when no
TH-positive neurons loss has been yet apparent, a decrease in
Aldh1a1 (Figures 3C–G) and, later, in TH and AADC expres-
sion (Figures 3G, 4A,B), and a dramatic loss of DAT (Figure 4C)
predetermined the fatal outcome for the dopamine system in
aged cFoxa1/2−/− animals (Figure 5). Considering that Foxa fac-
tors can bind to the 5′-regions of Aldh1a1, Aadc, and Th genes
(Lee et al., 2010; Soccio et al., 2011; Stott et al., 2013; Yang
et al., 2013), changes in their transcription levels likely represent a
molecular mechanism by which Foxa1/2 factors protect adult DA
neurons.
The data presented above demonstrate that the deletion of
Foxa1/2 ultimately led to a loss of TH-positive neurons in adult
mice. To find out whether these results are also clinically relevant,
we decided to check if the down-regulation of Foxa1/2 factors and
their target genes has been observed in other PD animal models
and in PD patients. Online databases of gene expression profil-
ing in clinical PD samples and animal models, namely National
Center for Adult Stem Cell Research Parkinson’s review database
(Sutherland et al., 2009) and ParkDB (Taccioli et al., 2011) pro-
vide a comprehensive and constantly updated resource for data
mining in a PD-related context. The ParkDB database also allows
cross-species comparison of human and mouse expression profil-
ing data. Thus, we searched online both of these databases for the
expression changes of Foxa1, Foxa2, Aldh1a1, Nr4a2, Aadc, Th,
En1, and Slc6a3. The levels of these mRNAs were down-regulated
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Table 2 | Levels of dopamine and its metabolites in the striata of mice 24 weeks after conditional ablation of Foxa1/2 factors in adult
dopamine neurons.
Line name n Dopamine (ng/mg) DOPAC (ng/mg) HVA (ng/mg)
Control 10 13.49± 1.0 0.87± 0.06 1.24± 0.12
cFoxa2−/− 6 12.8± 0.9 0.86± 0.06 1.16± 0.09
cFoxa1+/−/2−/− 10 11.92± 0.78 0.67± 0.04* 1.02± 0.07
cFoxa1/2−/− 5 6.27± 0.76*** 0.38± 0.05*** 0.67± 0.11**
The data, presented as mean values ± s.e.m., are normalized to the striatal weight; * p < 0.05, ** p < 0.01, *** p < 0.001 in comparison to control, as determined
by Student’s unpaired t-test. DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid.
in several studies comparing expression profiles of the SNpc sam-
ples from PD patients and age-matched healthy subjects (Hauser
et al., 2005; Zhang et al., 2005; Moran et al., 2006; Lesnick et al.,
2007), indicating that not only Foxa1/2 factors, but also several
Foxa1/2-regulated genes are affected in PD patients. Interestingly,
while the down-regulation of Foxa1/2 has been observed in the
SNpc, the levels of these factors did not significantly change
in other tissues of PD patients, such as putamen, cerebellum,
occipital cortex (Vogt et al., 2006) and whole blood (Scherzer
et al., 2007), possibly indicating a specific role of Foxa factors
in the SNpc neurons. Notably, the levels of Foxa1/2 also did not
change in the SNpc of transgenic mice overexpressing Hsp70 and
alpha-synuclein (dataset E-GEOD-4758) (Klucken et al., 2004),
suggesting that Foxa1/2 factors might not be contributing to
alpha-synuclein-induced pathology.
DISCUSSION
Both Foxa1 and Foxa2 are crucial for the specification and devel-
opment of DA neurons, as was demonstrated by inactivation of
these transcription factors prenatally (Ferri et al., 2007; Kittappa
et al., 2007; Stott et al., 2013). Moreover, about 30% of mice het-
erozygous for Foxa2 develop asymmetric loss of DA neurons in
the SNpc late in life (Kittappa et al., 2007). First, we sought to
study the role of Foxa2 in adult DA neurons by conditionally
inactivating the Foxa2 gene by a DA neuron-specific inducible
CreERT2 recombination (Engblom et al., 2008; Domanskyi et al.,
2011; Rieker et al., 2011). However, the ablation of only Foxa2
in the presence of intact Foxa1 alleles led neither to neurode-
generation nor to locomotor impairments in cFoxa2−/− mice
(Figures 1A–C). Moreover, we observed an up-regulation of
Foxa1 mRNA in the ventral midbrain samples from cFoxa2−/−
mice (Figure 1D). This up-regulation may be caused by a yet
undiscovered feedback loop mechanism to compensate for the
function of Foxa2 in adult DA neurons, explaining the absence
of phenotype in cFoxa2−/− mice. Indeed, Foxa1 and Foxa2 have
been reported to regulate the development of DA neurons in
a dose-dependent manner (Ferri et al., 2007). Both Foxa1 and
Foxa2 are important “pioneering” factors which open the chro-
matin for binding of other transcription regulators (Friedman
and Kaestner, 2006). Possibly, the Foxa factors have evolved to
compensate for the down-regulation of either protein.
In agreement with the redundant functions of Foxa factors,
locomotor impairments and movement asymmetry developed
only after conditional inactivation of both Foxa1 and Foxa2, but
not Foxa2 alone, in adult DA neurons (Figures 2A–E). Similar
phenotype was observed in our previous studies after conditional
ablation of polymerase I transcription initiation factor Ia (TifIa)
in adult DA neurons (Domanskyi et al., 2011; Rieker et al., 2011).
In cFoxa1/2−/− mice, deficits in locomotion became apparent 18
weeks after Foxa1/2 ablation when the double mutant mice exhib-
ited a reduced latency to fall off the rotarod. In the open field test
performed 21 weeks post-TAM, cFoxa1/2−/− mice showed locally
restricted but highly increased circling behavior with almost no
forward locomotion. Both behaviors reflect bradykinesia and
asymmetric movements, symptoms, the onset of which becomes
apparent upon loss of striatal DA content in patients with PD
(Taylor et al., 2010). Especially a circling behavior is a classical
symptom of unbalanced DA levels in PD, and it is often induced
by unilateral lesions (Heuer et al., 2012).
In cFoxa1/2−/− mice, there was no apparent loss of TH-
positive neurons either in the SNpc or in the VTA (Figures 3A–B)
up to 24 weeks after Foxa1/2 ablation. However, we detected
a significant down-regulation of Aldh1a1 in TH-positive DA
neurons of the ventral midbrain of cFoxa1/2−/− mice at
11 weeks after recombination (Figure 3C), that became even
more pronounced at 24 weeks, with TH-positive DA neu-
rons in the SNpc being more affected than those in the
VTA (Figures 3C–G). Aldh1a1 catalyses the oxidation of 3,4-
dihydroxyphenylacetaldehyde (DOPAL) to DOPAC which is then
converted to HVA in DA neurons (Marchitti et al., 2007). Thus,
down-regulation of Aldh1a1may also contribute to reduced levels
of both these dopaminemetabolites that occurred in cFoxa1/2−/−
mice 24 weeks after recombination (Table 2). A protective func-
tion of Aldh1a1 in DA neurons has been reported in several
studies (Anderson et al., 2011; Wey et al., 2012; Liu et al., 2014);
moreover, reduced Aldh1a1 expression and the loss of Aldh1a1-
positive DA neurons has been observed in post-mortem brain sec-
tions from PD patients (Liu et al., 2014). Interestingly, chromatin
immunoprecipitation (ChIP) studies identified two Foxa2 bind-
ing sites 5′ to the protein coding sequence of human and mouse
Aldh1a1 gene (Soccio et al., 2011; Yang et al., 2013), suggest-
ing that Foxa factors may directly regulate Aldh1a1 expression.
Concomitant with the down-regulation of striatal dopamine, the
observed reduction in Aldh1a1 expression was the earliest molec-
ular manifestation of functional disturbances in DA neurons
detectable 11 weeks after the conditional ablation of Foxa factors.
Interestingly, even though the number of TH-positive neu-
rons in cFoxa1/2−/− mice at 24 weeks after recombination did
not change, the TH immunostaining intensity in the ventral
midbrain of cFoxa1/2−/− mice was lower than that of controls
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FIGURE 3 | Loss of the Aldh1a1 expression in adult dopamine
neurons precedes the onset of locomotor impairments in
cFoxa1/2−/− mice. (A,B) Quantification of tyrosine hydroxylase
(TH)-positive neurons in the SNpc (A) or in the VTA (B) of control,
cFoxa1+/−/2−/−, and cFoxa1/2−/− mice 24 weeks post-TAM (n = 4, 3,
and 5, respectively). (C–F) Quantification of aldehyde dehydrogenase 1
family, member A1 (Aldh1a1)-positive neurons in the ventral midbrain
(C,F), SNpc (D) or VTA (E) of control, cFoxa1+/−/2−/−, and cFoxa1/2−/−
mice 11 weeks (C) and 24 weeks (D–F) post-TAM expressed relative to
the number of TH-positive neurons (n = 4, 3, and 5, respectively). (G)
Representative microphotographs of TH (red) and Aldh1a1 (green)
immunofluorescent staining and co-localization of these proteins and
DAPI (blue) in the ventral midbrain sections from control and
cFoxa1/2−/− mice 24 weeks post-TAM. Scale bar, 200µm for overviews
and 50µm for insets. ∗p < 0.05, ∗∗p < 0.01 in comparison to control, as
determined by Student’s unpaired t-test.
(Figures 3G, 4A) and the Th mRNA levels also had a tendency
towards a decrease (Supplementary Figure 2). We observed even
more pronounced loss of immunostaining intensity for two other
markers of DA neurons, AADC and DAT (Figures 4B,C), paral-
leled by altered morphology of these cells (Figure 3G), suggesting
that the ablation of Foxa1 and Foxa2 causedDA neurons to gradu-
ally lose their dopaminergic phenotype. Similar down-regulation
of Aldh1a1, TH, DAT, and AADC was also reported in post-
mitotic DA neurons after prenatal ablation of Foxa1/2 (Stott et al.,
2013) that is in a good agreement with our data. However, in that
study, the authors also detected a decrease in TH-positive neu-
rons both pre- and postnatally. On the contrary, in our model,
when inactivation of both factors occurred in adult DA neurons,
we did not detect any loss of TH-positive cells up to 24 weeks
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FIGURE 4 | Down-regulation of dopamine neuronal markers in
cFoxa1/2−/− mice. (A–C) Representative microphotographs of tyrosine
hydroxylase (TH) (A), aromatic amino acid decarboxylase (AADC) (B) and
dopamine transporter (DAT) (C) immunostaining in the ventral midbrain of
control and cFoxa1/2−/− mice 24 weeks post-TAM. Scale bar, 500µm.
post-TAM. These data suggest that Foxa1/2 factors are essential
for DA survival during their maturation and specification, while,
similarly to PD, additional epigenetic cues (such as environmental
factors, mitochondrial stress or aging) are required for the onset
of neurodegeneration when Foxa factors are inactivated inmature
DA neurons.
Foxa2 can regulate TH expression directly and/or coopera-
tively with Nurr1 (Lee et al., 2010), and there are three Foxa2
FIGURE 5 | Loss of TH-positive adult dopamine neurons in aged
cFoxa1/2−/− mice. (A) Striatal dopamine content in control or cFoxa1/2−/−
mice 78 weeks after TAM treatment (n = 6 and 3, respectively). (B)
Quantification of tyrosine hydroxylase (TH)-positive neurons in the SNpc of
control and cFoxa1/2−/− mice at the same time point (n = 3). (C,D)
Representative microphotographs of TH (C) and aromatic amino acid
decarboxylase (AADC) (D) immunostaining in the ventral midbrain of
control and cFoxa1/2−/− mice. Scale bar, 500µm. ∗p < 0.05, ∗∗∗p < 0.001
in comparison to control, as determined by Student’s unpaired t-test.
binding sites in the promoter region of the mouse Aadc gene
identified by ChIP (Soccio et al., 2011; Yang et al., 2013). It has
also been shown that Foxa1/2 loss leads to lower occupancy of
Aadc and Th gene promoters by Nurr1 that, without affecting the
levels of Nurr1 itself, results in the down-regulation of AADC
in post-mitotic DA neurons (Stott et al., 2013). Of note, the
loss of Foxa1/2 did not lead to down-regulation of the levels
of either Nurr1 or several other factors important for the func-
tions of DA neurons in the ventral midbrain (Supplementary
Figure 2). However, consistent with the role of Foxa proteins as
“pioneer” factors that increase chromatin accessibility for other
transcriptional regulators (Friedman and Kaestner, 2006), the loss
of Foxa1/2 might have affected the ability of other transcription
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factors, including Nurr1, to bind their target promoters in adult
DA neurons, as it was observed in a study with the prenatal
ablation of Foxa1/2 factors (Stott et al., 2013).
By mining the available gene expression profiling data, we
have found that the expression levels of Foxa1 and Foxa2, as
well as Aldh1a1, Nr4a2, Aadc, Th, En1, and Slc6a3 were also
down-regulated in the SNpc, but not in other brain regions or tis-
sue samples from PD patients. However, the profiling data from
patients’ SNpc samples should be interpreted cautiously, because
the apparent down-regulation of these genes might just reflect the
loss of DA neurons expressing them. Nevertheless, in the con-
text of our results and previously published data (Kittappa et al.,
2007; Stott et al., 2013), the observed down-regulation of Foxa1/2
in post-mortem samples from PD patients suggests that Foxa1/2
factors and their target genes may have a specific role in the SNpc
and contribute to neurodegeneration in PD patients.
In summary, we show that, similar to their role in the embry-
onic development (Ferri et al., 2007; Stott et al., 2013), Foxa1 can
compensate for the loss of Foxa2 in adult DA neurons. Thus, a
functional redundancy between Foxa1 and Foxa2 proteins, ini-
tially observed during embryonic development, is also evident in
adult DA neurons. We have further demonstrated that the abla-
tion of Foxa factors in adult DA neurons initially led to the loss of
Aldh1a1 expression accompanied by the loss of striatal dopamine
and locomotor impairments in the rotarod and open field tests.
Foxa factors may regulate Aldh1a1 directly by binding to the
gene’s promoter (Soccio et al., 2011; Yang et al., 2013) and/or
indirectly by opening chromatin and facilitating the binding of
other transcription factors (Friedman and Kaestner, 2006). This
data suggests that Foxa1/2 ablation led to the loss of dopaminergic
phenotype in SNpc DA neurons that was further confirmed by the
observed down-regulation of AADC and DAT expression in the
SNpc. Ultimately, we detected a significant loss of TH-positive DA
neurons in aged cFoxa1/2−/− mice (Figures 5B,C), resembling
the course of events during the PD pathology in humans.
Altogether, our data establish a protective role of Foxa factors
in the maintenance of dopamine neurons in vivo. Drugs targeting
cytoprotective pathways in DA neurons of human patients with
PD are already effectively used or being tested in clinical stud-
ies (Allain et al., 2008; Youdim, 2010; Pahwa and Lyons, 2014).
The transcription factors from the Foxa family could become
additional candidates for such therapeutic strategies.
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